APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologic Medications for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biologic Medications for Psoriasis Market Analysis and Forecast 2026-2032

27 December 2025207 pages

Choose your research edition.

Industry ResearchBiologic Medications for Psoriasis Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologic Medications for Psoriasis Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Biologic Medications for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologic Medications for Psoriasis Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologic Medications for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biologic Medications for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for Biologic Medications for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologic Medications for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biologic Medications for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Biologic Medications for Psoriasis sales, projected growth trends, production technology, application and end-user industry.

Biologic Medications for Psoriasis Segment by Company

AbbVie Biotechnology

Amgen

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb

Eli Lilly

Janssen Biotech

Kyowa Kirin

LEO Pharma

Novartis

Ortho Dermatologics

Pfizer

Samsung Bioepis

Tiefenbacher Pharmaceuticals

UCB

Dalian Yawei Pharmaceutical

Hanwha Chemical

China Medical System

Qilu Pharmaceutical

Biologic Medications for Psoriasis Segment by Type

Interleukin Inhibitors

Tyrosine Kinase Inhibitors

Phosphodiesterase Inhibitors

TNF-α Inhibitors

Other

Biologic Medications for Psoriasis Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Biologic Medications for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Biologic Medications for Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologic Medications for Psoriasis sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologic Medications for Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Interleukin Inhibitors Major Manufacturers Table 3. Tyrosine Kinase Inhibitors Major Manufacturers Table 4. Phosphodiesterase Inhibitors Major Manufacturers Table 5. TNF-α Inhibitors Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global Biologic Medications for Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacies Major Manufacturers Table 9. Hospital and Clinic Major Manufacturers Table 10. Other Major Manufacturers Table 11. Biologic Medications for Psoriasis Industry Trends Table 12. Biologic Medications for Psoriasis Industry Drivers Table 13. Biologic Medications for Psoriasis Industry Opportunities and Challenges Table 14. Biologic Medications for Psoriasis Industry Restraints Table 15. Global Biologic Medications for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Biologic Medications for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Biologic Medications for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2026) Table 19. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2027-2032) Table 20. Global Biologic Medications for Psoriasis Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Biologic Medications for Psoriasis Sales by Region (2021-2026) & (K Units) Table 22. Global Biologic Medications for Psoriasis Sales by Region (2027-2032) & (K Units) Table 23. Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2026) Table 24. Global Biologic Medications for Psoriasis Sales Market Share by Region (2027-2032) Table 25. Global Biologic Medications for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Biologic Medications for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Biologic Medications for Psoriasis Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Biologic Medications for Psoriasis Sales Market Share by Manufacturers (2021-2026) Table 29. Global Biologic Medications for Psoriasis Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Biologic Medications for Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Biologic Medications for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Biologic Medications for Psoriasis Manufacturers, Product Type & Application Table 33. Global Biologic Medications for Psoriasis Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Biologic Medications for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Biologic Medications for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2026) Table 40. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2027-2032) Table 41. Global Biologic Medications for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 43. Global Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 44. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2026) Table 45. Global Biologic Medications for Psoriasis Sales Market Share by Type (2027-2032) Table 46. Global Biologic Medications for Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 47. Global Biologic Medications for Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 48. Global Biologic Medications for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2026) Table 52. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2027-2032) Table 53. Global Biologic Medications for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 55. Global Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 56. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2026) Table 57. Global Biologic Medications for Psoriasis Sales Market Share by Application (2027-2032) Table 58. Global Biologic Medications for Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 59. Global Biologic Medications for Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 60. AbbVie Biotechnology Company Information Table 61. AbbVie Biotechnology Business Overview Table 62. AbbVie Biotechnology Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio Table 64. AbbVie Biotechnology Recent Development Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Amgen Biologic Medications for Psoriasis Product Portfolio Table 69. Amgen Recent Development Table 70. Boehringer Ingelheim Pharmaceuticals Company Information Table 71. Boehringer Ingelheim Pharmaceuticals Business Overview Table 72. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 74. Boehringer Ingelheim Pharmaceuticals Recent Development Table 75. Bristol-Myers Squibb Company Information Table 76. Bristol-Myers Squibb Business Overview Table 77. Bristol-Myers Squibb Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio Table 79. Bristol-Myers Squibb Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Eli Lilly Biologic Medications for Psoriasis Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Janssen Biotech Company Information Table 86. Janssen Biotech Business Overview Table 87. Janssen Biotech Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Janssen Biotech Biologic Medications for Psoriasis Product Portfolio Table 89. Janssen Biotech Recent Development Table 90. Kyowa Kirin Company Information Table 91. Kyowa Kirin Business Overview Table 92. Kyowa Kirin Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio Table 94. Kyowa Kirin Recent Development Table 95. LEO Pharma Company Information Table 96. LEO Pharma Business Overview Table 97. LEO Pharma Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. LEO Pharma Biologic Medications for Psoriasis Product Portfolio Table 99. LEO Pharma Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Novartis Biologic Medications for Psoriasis Product Portfolio Table 104. Novartis Recent Development Table 105. Ortho Dermatologics Company Information Table 106. Ortho Dermatologics Business Overview Table 107. Ortho Dermatologics Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio Table 109. Ortho Dermatologics Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer Biologic Medications for Psoriasis Product Portfolio Table 114. Pfizer Recent Development Table 115. Samsung Bioepis Company Information Table 116. Samsung Bioepis Business Overview Table 117. Samsung Bioepis Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio Table 119. Samsung Bioepis Recent Development Table 120. Tiefenbacher Pharmaceuticals Company Information Table 121. Tiefenbacher Pharmaceuticals Business Overview Table 122. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 124. Tiefenbacher Pharmaceuticals Recent Development Table 125. UCB Company Information Table 126. UCB Business Overview Table 127. UCB Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. UCB Biologic Medications for Psoriasis Product Portfolio Table 129. UCB Recent Development Table 130. Dalian Yawei Pharmaceutical Company Information Table 131. Dalian Yawei Pharmaceutical Business Overview Table 132. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 134. Dalian Yawei Pharmaceutical Recent Development Table 135. Hanwha Chemical Company Information Table 136. Hanwha Chemical Business Overview Table 137. Hanwha Chemical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio Table 139. Hanwha Chemical Recent Development Table 140. China Medical System Company Information Table 141. China Medical System Business Overview Table 142. China Medical System Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. China Medical System Biologic Medications for Psoriasis Product Portfolio Table 144. China Medical System Recent Development Table 145. Qilu Pharmaceutical Company Information Table 146. Qilu Pharmaceutical Business Overview Table 147. Qilu Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 149. Qilu Pharmaceutical Recent Development Table 150. North America Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 151. North America Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 152. North America Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 153. North America Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 154. North America Biologic Medications for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 155. North America Biologic Medications for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 156. North America Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 157. North America Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 158. North America Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 159. North America Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 160. North America Biologic Medications for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 161. North America Biologic Medications for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 162. North America Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. North America Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. North America Biologic Medications for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. North America Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 166. North America Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 167. North America Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 168. North America Biologic Medications for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 169. North America Biologic Medications for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 170. United States Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 171. Canada Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 172. Mexico Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 173. Europe Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 174. Europe Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 175. Europe Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 176. Europe Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 177. Europe Biologic Medications for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 178. Europe Biologic Medications for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 179. Europe Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 180. Europe Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 181. Europe Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 182. Europe Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 183. Europe Biologic Medications for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 184. Europe Biologic Medications for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 185. Europe Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. Europe Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. Europe Biologic Medications for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. Europe Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 189. Europe Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 190. Europe Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 191. Europe Biologic Medications for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 192. Europe Biologic Medications for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 193. Germany Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 194. France Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 195. U.K. Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 196. Italy Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 197. Russia Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 198. Spain Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 199. Netherlands Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 200. Switzerland Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 201. Sweden Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 202. Poland Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 203. China Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 204. China Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 205. China Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 206. China Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 207. China Biologic Medications for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 208. China Biologic Medications for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 209. China Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 210. China Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 211. China Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 212. China Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 213. China Biologic Medications for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 214. China Biologic Medications for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 215. Asia Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 216. Asia Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 217. Asia Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 218. Asia Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 219. Asia Biologic Medications for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 220. Asia Biologic Medications for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 221. Asia Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 222. Asia Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 223. Asia Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 224. Asia Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 225. Asia Biologic Medications for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 226. Asia Biologic Medications for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 227. Asia Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. Asia Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. Asia Biologic Medications for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. Asia Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. Asia Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 232. Asia Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 233. Asia Biologic Medications for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 234. Asia Biologic Medications for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 235. Japan Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 236. South Korea Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 237. India Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 238. Australia Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 239. Taiwan Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 240. Southeast Asia Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 241. SAMEA Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 242. SAMEA Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 243. SAMEA Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 244. SAMEA Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 245. SAMEA Biologic Medications for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 246. SAMEA Biologic Medications for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 247. SAMEA Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 248. SAMEA Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 249. SAMEA Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 250. SAMEA Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 251. SAMEA Biologic Medications for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 252. SAMEA Biologic Medications for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 253. SAMEA Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 254. SAMEA Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 255. SAMEA Biologic Medications for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 256. SAMEA Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 257. SAMEA Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 258. SAMEA Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 259. SAMEA Biologic Medications for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 260. SAMEA Biologic Medications for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 261. Brazil Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 262. Argentina Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 263. Chile Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 264. Colombia Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 265. Peru Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 266. Saudi Arabia Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 267. Israel Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 268. UAE Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 269. Turkey Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 270. Iran Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 271. Egypt Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Table 272. Key Raw Materials Table 273. Raw Materials Key Suppliers Table 274. Biologic Medications for Psoriasis Distributors List Table 275. Biologic Medications for Psoriasis Customers List Table 276. Research Programs/Design for This Report Table 277. Authors List of This Report Table 278. Secondary Sources Table 279. Primary Sources List of Figures Figure 1. Biologic Medications for Psoriasis Image Figure 2. Global Biologic Medications for Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologic Medications for Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Interleukin Inhibitors Image Figure 5. Tyrosine Kinase Inhibitors Image Figure 6. Phosphodiesterase Inhibitors Image Figure 7. TNF-α Inhibitors Image Figure 8. Other Image Figure 9. Global Biologic Medications for Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biologic Medications for Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacies Image Figure 12. Hospital and Clinic Image Figure 13. Other Image Figure 14. Global Biologic Medications for Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 16. Global Biologic Medications for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Biologic Medications for Psoriasis Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2032) Figure 19. Global Biologic Medications for Psoriasis Sales (2021-2032) & (K Units) Figure 20. Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Biologic Medications for Psoriasis Sales YoY (2021-2032) & (K Units) Figure 23. Europe Biologic Medications for Psoriasis Sales YoY (2021-2032) & (K Units) Figure 24. China Biologic Medications for Psoriasis Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Biologic Medications for Psoriasis Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Biologic Medications for Psoriasis Sales YoY (2021-2032) & (K Units) Figure 27. Global Biologic Medications for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Biologic Medications for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Biologic Medications for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Biologic Medications for Psoriasis Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032) Figure 33. Global Biologic Medications for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Biologic Medications for Psoriasis Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032) Figure 36. Global Biologic Medications for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Biologic Medications for Psoriasis Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032) Figure 39. Global Biologic Medications for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Biologic Medications for Psoriasis Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032) Figure 42. North America Biologic Medications for Psoriasis Revenue Share by Type (2021-2032) Figure 43. North America Biologic Medications for Psoriasis Sales Share by Type (2021-2032) Figure 44. North America Biologic Medications for Psoriasis Revenue Share by Application (2021-2032) Figure 45. North America Biologic Medications for Psoriasis Sales Share by Application (2021-2032) Figure 46. North America Biologic Medications for Psoriasis Revenue Share by Country (2021-2032) Figure 47. North America Biologic Medications for Psoriasis Sales Share by Country (2021-2032) Figure 48. Europe Biologic Medications for Psoriasis Revenue Share by Type (2021-2032) Figure 49. Europe Biologic Medications for Psoriasis Sales Share by Type (2021-2032) Figure 50. Europe Biologic Medications for Psoriasis Revenue Share by Application (2021-2032) Figure 51. Europe Biologic Medications for Psoriasis Sales Share by Application (2021-2032) Figure 52. Europe Biologic Medications for Psoriasis Revenue Share by Country (2021-2032) Figure 53. Europe Biologic Medications for Psoriasis Sales Share by Country (2021-2032) Figure 54. China Biologic Medications for Psoriasis Revenue Share by Type (2021-2032) Figure 55. China Biologic Medications for Psoriasis Sales Share by Type (2021-2032) Figure 56. China Biologic Medications for Psoriasis Revenue Share by Application (2021-2032) Figure 57. China Biologic Medications for Psoriasis Sales Share by Application (2021-2032) Figure 58. Asia Biologic Medications for Psoriasis Revenue Share by Type (2021-2032) Figure 59. Asia Biologic Medications for Psoriasis Sales Share by Type (2021-2032) Figure 60. Asia Biologic Medications for Psoriasis Revenue Share by Application (2021-2032) Figure 61. Asia Biologic Medications for Psoriasis Sales Share by Application (2021-2032) Figure 62. Asia Biologic Medications for Psoriasis Revenue Share by Country (2021-2032) Figure 63. Asia Biologic Medications for Psoriasis Sales Share by Country (2021-2032) Figure 64. SAMEA Biologic Medications for Psoriasis Revenue Share by Type (2021-2032) Figure 65. SAMEA Biologic Medications for Psoriasis Sales Share by Type (2021-2032) Figure 66. SAMEA Biologic Medications for Psoriasis Revenue Share by Application (2021-2032) Figure 67. SAMEA Biologic Medications for Psoriasis Sales Share by Application (2021-2032) Figure 68. SAMEA Biologic Medications for Psoriasis Revenue Share by Country (2021-2032) Figure 69. SAMEA Biologic Medications for Psoriasis Sales Share by Country (2021-2032) Figure 70. Biologic Medications for Psoriasis Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Biologic Medications for Psoriasis Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Interleukin Inhibitors
  • Tyrosine Kinase Inhibitors
  • Phosphodiesterase Inhibitors
  • TNF-α Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • AbbVie Biotechnology
  • Amgen
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly
  • Janssen Biotech
  • Kyowa Kirin
  • LEO Pharma
  • Novartis
  • Ortho Dermatologics
  • Pfizer
  • Samsung Bioepis
  • Tiefenbacher Pharmaceuticals
  • UCB
  • Dalian Yawei Pharmaceutical
  • Hanwha Chemical
  • China Medical System
  • Qilu Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biologic Medications for Psoriasis Market by Type
  3. 1.2.1 Global Biologic Medications for Psoriasis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Interleukin Inhibitors
  5. 1.2.3 Tyrosine Kinase Inhibitors
  6. 1.2.4 Phosphodiesterase Inhibitors
  7. 1.2.5 TNF-α Inhibitors
  8. 1.2.6 Other
  9. 1.3 Biologic Medications for Psoriasis Market by Application
  10. 1.3.1 Global Biologic Medications for Psoriasis Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacies
  12. 1.3.3 Hospital and Clinic
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Biologic Medications for Psoriasis Market Dynamics
  1. 2.1 Biologic Medications for Psoriasis Industry Trends
  2. 2.2 Biologic Medications for Psoriasis Industry Drivers
  3. 2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
  4. 2.4 Biologic Medications for Psoriasis Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Biologic Medications for Psoriasis Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Biologic Medications for Psoriasis Revenue by Region
  3. 3.2.1 Global Biologic Medications for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biologic Medications for Psoriasis Revenue by Region (2021-2026)
  5. 3.2.3 Global Biologic Medications for Psoriasis Revenue by Region (2027-2032)
  6. 3.2.4 Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Biologic Medications for Psoriasis Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Biologic Medications for Psoriasis Sales by Region
  9. 3.4.1 Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Biologic Medications for Psoriasis Sales by Region (2021-2026)
  11. 3.4.3 Global Biologic Medications for Psoriasis Sales by Region (2027-2032)
  12. 3.4.4 Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Biologic Medications for Psoriasis Revenue by Manufacturers
  2. 4.1.1 Global Biologic Medications for Psoriasis Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Biologic Medications for Psoriasis Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Biologic Medications for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biologic Medications for Psoriasis Sales by Manufacturers
  6. 4.2.1 Global Biologic Medications for Psoriasis Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Biologic Medications for Psoriasis Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Biologic Medications for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Biologic Medications for Psoriasis Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Biologic Medications for Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Biologic Medications for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Biologic Medications for Psoriasis Manufacturers, Product Type & Application
  13. 4.7 Global Biologic Medications for Psoriasis Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Biologic Medications for Psoriasis Market CR5 and HHI
  16. 4.8.2 2025 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3
5 Biologic Medications for Psoriasis Market by Type
  1. 5.1 Global Biologic Medications for Psoriasis Revenue by Type
  2. 5.1.1 Global Biologic Medications for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Biologic Medications for Psoriasis Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Biologic Medications for Psoriasis Sales by Type
  6. 5.2.1 Global Biologic Medications for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologic Medications for Psoriasis Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032)
  9. 5.3 Global Biologic Medications for Psoriasis Price by Type
6 Biologic Medications for Psoriasis Market by Application
  1. 6.1 Global Biologic Medications for Psoriasis Revenue by Application
  2. 6.1.1 Global Biologic Medications for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Biologic Medications for Psoriasis Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Biologic Medications for Psoriasis Sales by Application
  6. 6.2.1 Global Biologic Medications for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Biologic Medications for Psoriasis Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032)
  9. 6.3 Global Biologic Medications for Psoriasis Price by Application
7 Company Profiles
  1. 7.1 AbbVie Biotechnology
  2. 7.1.1 AbbVie Biotechnology Company Information
  3. 7.1.2 AbbVie Biotechnology Business Overview
  4. 7.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
  6. 7.1.5 AbbVie Biotechnology Recent Developments
  7. 7.2 Amgen
  8. 7.2.1 Amgen Company Information
  9. 7.2.2 Amgen Business Overview
  10. 7.2.3 Amgen Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
  12. 7.2.5 Amgen Recent Developments
  13. 7.3 Boehringer Ingelheim Pharmaceuticals
  14. 7.3.1 Boehringer Ingelheim Pharmaceuticals Company Information
  15. 7.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  16. 7.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Eli Lilly
  26. 7.5.1 Eli Lilly Company Information
  27. 7.5.2 Eli Lilly Business Overview
  28. 7.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
  30. 7.5.5 Eli Lilly Recent Developments
  31. 7.6 Janssen Biotech
  32. 7.6.1 Janssen Biotech Company Information
  33. 7.6.2 Janssen Biotech Business Overview
  34. 7.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
  36. 7.6.5 Janssen Biotech Recent Developments
  37. 7.7 Kyowa Kirin
  38. 7.7.1 Kyowa Kirin Company Information
  39. 7.7.2 Kyowa Kirin Business Overview
  40. 7.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
  42. 7.7.5 Kyowa Kirin Recent Developments
  43. 7.8 LEO Pharma
  44. 7.8.1 LEO Pharma Company Information
  45. 7.8.2 LEO Pharma Business Overview
  46. 7.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
  48. 7.8.5 LEO Pharma Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
  54. 7.9.5 Novartis Recent Developments
  55. 7.10 Ortho Dermatologics
  56. 7.10.1 Ortho Dermatologics Company Information
  57. 7.10.2 Ortho Dermatologics Business Overview
  58. 7.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
  60. 7.10.5 Ortho Dermatologics Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Samsung Bioepis
  68. 7.12.1 Samsung Bioepis Company Information
  69. 7.12.2 Samsung Bioepis Business Overview
  70. 7.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
  72. 7.12.5 Samsung Bioepis Recent Developments
  73. 7.13 Tiefenbacher Pharmaceuticals
  74. 7.13.1 Tiefenbacher Pharmaceuticals Company Information
  75. 7.13.2 Tiefenbacher Pharmaceuticals Business Overview
  76. 7.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  78. 7.13.5 Tiefenbacher Pharmaceuticals Recent Developments
  79. 7.14 UCB
  80. 7.14.1 UCB Company Information
  81. 7.14.2 UCB Business Overview
  82. 7.14.3 UCB Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
  84. 7.14.5 UCB Recent Developments
  85. 7.15 Dalian Yawei Pharmaceutical
  86. 7.15.1 Dalian Yawei Pharmaceutical Company Information
  87. 7.15.2 Dalian Yawei Pharmaceutical Business Overview
  88. 7.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  90. 7.15.5 Dalian Yawei Pharmaceutical Recent Developments
  91. 7.16 Hanwha Chemical
  92. 7.16.1 Hanwha Chemical Company Information
  93. 7.16.2 Hanwha Chemical Business Overview
  94. 7.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
  96. 7.16.5 Hanwha Chemical Recent Developments
  97. 7.17 China Medical System
  98. 7.17.1 China Medical System Company Information
  99. 7.17.2 China Medical System Business Overview
  100. 7.17.3 China Medical System Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
  102. 7.17.5 China Medical System Recent Developments
  103. 7.18 Qilu Pharmaceutical
  104. 7.18.1 Qilu Pharmaceutical Company Information
  105. 7.18.2 Qilu Pharmaceutical Business Overview
  106. 7.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  108. 7.18.5 Qilu Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Biologic Medications for Psoriasis Market Size by Type
  2. 8.1.1 North America Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  3. 8.1.2 North America Biologic Medications for Psoriasis Sales by Type (2021-2032)
  4. 8.1.3 North America Biologic Medications for Psoriasis Price by Type (2021-2032)
  5. 8.2 North America Biologic Medications for Psoriasis Market Size by Application
  6. 8.2.1 North America Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  7. 8.2.2 North America Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 8.2.3 North America Biologic Medications for Psoriasis Price by Application (2021-2032)
  9. 8.3 North America Biologic Medications for Psoriasis Market Size by Country
  10. 8.3.1 North America Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Biologic Medications for Psoriasis Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Biologic Medications for Psoriasis Market Size by Type
  2. 9.1.1 Europe Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  3. 9.1.2 Europe Biologic Medications for Psoriasis Sales by Type (2021-2032)
  4. 9.1.3 Europe Biologic Medications for Psoriasis Price by Type (2021-2032)
  5. 9.2 Europe Biologic Medications for Psoriasis Market Size by Application
  6. 9.2.1 Europe Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  7. 9.2.2 Europe Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 9.2.3 Europe Biologic Medications for Psoriasis Price by Application (2021-2032)
  9. 9.3 Europe Biologic Medications for Psoriasis Market Size by Country
  10. 9.3.1 Europe Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Biologic Medications for Psoriasis Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Biologic Medications for Psoriasis Market Size by Type
  2. 10.1.1 China Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  3. 10.1.2 China Biologic Medications for Psoriasis Sales by Type (2021-2032)
  4. 10.1.3 China Biologic Medications for Psoriasis Price by Type (2021-2032)
  5. 10.2 China Biologic Medications for Psoriasis Market Size by Application
  6. 10.2.1 China Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  7. 10.2.2 China Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 10.2.3 China Biologic Medications for Psoriasis Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biologic Medications for Psoriasis Market Size by Type
  2. 11.1.1 Asia Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  3. 11.1.2 Asia Biologic Medications for Psoriasis Sales by Type (2021-2032)
  4. 11.1.3 Asia Biologic Medications for Psoriasis Price by Type (2021-2032)
  5. 11.2 Asia Biologic Medications for Psoriasis Market Size by Application
  6. 11.2.1 Asia Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  7. 11.2.2 Asia Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 11.2.3 Asia Biologic Medications for Psoriasis Price by Application (2021-2032)
  9. 11.3 Asia Biologic Medications for Psoriasis Market Size by Country
  10. 11.3.1 Asia Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Biologic Medications for Psoriasis Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biologic Medications for Psoriasis Market Size by Type
  2. 12.1.1 SAMEA Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Biologic Medications for Psoriasis Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Biologic Medications for Psoriasis Price by Type (2021-2032)
  5. 12.2 SAMEA Biologic Medications for Psoriasis Market Size by Application
  6. 12.2.1 SAMEA Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Biologic Medications for Psoriasis Price by Application (2021-2032)
  9. 12.3 SAMEA Biologic Medications for Psoriasis Market Size by Country
  10. 12.3.1 SAMEA Biologic Medications for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Biologic Medications for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Biologic Medications for Psoriasis Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Biologic Medications for Psoriasis Value Chain Analysis
  2. 13.1.1 Biologic Medications for Psoriasis Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Biologic Medications for Psoriasis Production Mode & Process
  6. 13.2 Biologic Medications for Psoriasis Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Biologic Medications for Psoriasis Distributors
  9. 13.2.3 Biologic Medications for Psoriasis Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst